product1 distinct publisher
Half of severe alopecia patients on upadacitinib hit 80% scalp coverage by week 24
The JAMA Dermatology results published August 12 push an already-approved arthritis pill toward a new indication, which turns interesting science into a prior-authorization question about who counts as a responder.
Publishers:interestingengineering.com
Reality
- Evidence45
- Adoption20
- Hype gap+38
- Incentives
- Insufficient
- Confidence